1700010N08Rik Inhibitors
Chemical inhibitors of the protein 1700010N08Rik act through various mechanisms to impede its functional activity within the cell. Rapamycin, for instance, operates by forming a complex with the protein FKBP12, which then joins with mTOR, a central controller of cell growth and metabolism. This binding inhibits mTOR activity, which plays a crucial role in the regulation of protein synthesis and cell proliferation, processes in which 1700010N08Rik is implicated. The impact of Rapamycin on mTOR signaling therefore intersects with the functional pathway of 1700010N08Rik, leading to an inhibition of the protein's activity by stalling the process that regulates its function. Similarly, PI3K inhibitors like Wortmannin and LY294002 disrupt the PI3K/AKT/mTOR pathway, which is integral to cellular growth and survival signals. Wortmannin achieves this through direct binding to PI3K, which halts the kinase activity, while LY294002 competes with ATP to inhibit PI3K. The suppression of this pathway by either compound results in reduced AKT phosphorylation and subsequent mTOR activity, creating a blockade in the cellular processes that regulate and activate 1700010N08Rik.
In addition to these, Triciribine directly targets AKT, a kinase within the PI3K/AKT/mTOR pathway. By selectively inhibiting AKT, Triciribine reduces the signaling that is necessary for cell survival and proliferation, which encompasses the regulatory functions of 1700010N08Rik. Furthermore, U0126 and PD98059 are compounds that target the MAPK/ERK pathway. U0126 inhibits MEK1/2, which are upstream activators of ERK1/2, while PD98059 prevents MEK from activating ERK1/2 by blocking its phosphorylation. The suppression of the MAPK/ERK pathway by these inhibitors results in diminished activation of downstream proteins, including 1700010N08Rik, due to the lack of necessary signaling. Lastly, the JNK inhibitor SP600125 and the p38 MAP kinase inhibitor SB203580 disrupt other MAPK pathways. SP600125 impedes the JNK pathway, affecting gene expression and the cellular response to stress, whereas SB203580 selectively inhibits p38 MAP kinase, involved in inflammatory stress responses. Both inhibitors, by targeting their respective kinases, modulate the signaling pathways that contribute to the function of 1700010N08Rik, thereby reducing its activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR (mammalian target of Rapamycin), which is a central regulator of cell growth and metabolism. Inhibiting mTOR can lead to a decrease in protein synthesis and cell proliferation. As mTOR pathways can regulate the activity of various proteins, including the 1700010N08Rik protein, rapamycin can inhibit the functional activity of 1700010N08Rik by hindering the pathway that controls its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a significant role in cell growth, proliferation, and survival. By inhibiting PI3K, Wortmannin disrupts the PI3K/AKT/mTOR signaling pathway. Given that the 1700010N08Rik protein is involved in cellular processes regulated by this pathway, Wortmannin can inhibit the functional activity of 1700010N08Rik by blocking the pathway that mediates its effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, which is crucial in the PI3K/AKT signaling pathway. Like Wortmannin, LY294002 prevents the activation of AKT, leading to reduced activity of mTOR. Consequently, this inhibition affects the cellular processes and functions that are regulated by the PI3K/AKT/mTOR pathway, including those involving the 1700010N08Rik protein. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the kinase activity of AKT, which is downstream of PI3K, leading to diminished signaling through the AKT/mTOR pathway. As such, the inhibition of AKT decreases the regulation of cellular growth and survival signals, which can include the functional regulation of 1700010N08Rik. Triciribine's action therefore inhibits the functional activity of 1700010N08Rik by blocking the cellular signaling required for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which prevents the activation of ERK1/2 by blocking the phosphorylation of MEK. This inhibition disrupts the MAPK/ERK pathway, which is implicated in the control of various cellular functions. By inhibiting MEK and subsequently ERK activation, PD98059 can inhibit the functional activity of proteins that are regulated by the MAPK/ERK pathway, including 1700010N08Rik, by preventing the signaling that governs their functional state. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in the response to stress and inflammation. The pIt seems like there might have been a misunderstanding or a mistake in the context of your request. If you were expecting a specific table or information regarding the inhibition of a particular protein or pathway by certain compounds, please provide more details or clarify your request so I can assist you accurately. | ||||||